Leerink Partnrs Brokers Boost Earnings Estimates for Pfizer

Pfizer Inc. (NYSE:PFE) – Leerink Partnrs raised their FY2025 earnings per share estimates for Pfizer in a research report issued on Tuesday, November 4th. Leerink Partnrs analyst D. Risinger now forecasts that the biopharmaceutical company will post earnings of $3.11 per share for the year, up from their previous estimate of $3.04. The consensus estimate for Pfizer’s current full-year earnings is $2.95 per share. Leerink Partnrs also issued estimates for Pfizer’s FY2026 earnings at $3.20 EPS, FY2027 earnings at $3.16 EPS, FY2028 earnings at $2.57 EPS and FY2029 earnings at $2.24 EPS.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, November 4th. The biopharmaceutical company reported $0.87 EPS for the quarter, beating the consensus estimate of $0.79 by $0.08. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The firm had revenue of $16.65 billion for the quarter, compared to the consensus estimate of $16.94 billion. Pfizer has set its FY 2025 guidance at 3.000-3.150 EPS.

A number of other equities analysts have also weighed in on the company. Morgan Stanley dropped their price objective on Pfizer from $33.00 to $32.00 and set an “equal weight” rating for the company in a research note on Friday, October 10th. UBS Group reissued a “neutral” rating and issued a $28.00 price target on shares of Pfizer in a report on Wednesday, October 1st. Sanford C. Bernstein restated a “market perform” rating and issued a $30.00 price target on shares of Pfizer in a research note on Friday, October 31st. Citigroup lifted their price objective on shares of Pfizer from $25.00 to $26.00 and gave the company a “neutral” rating in a research report on Wednesday, August 6th. Finally, The Goldman Sachs Group reissued a “neutral” rating and issued a $26.00 target price on shares of Pfizer in a report on Wednesday. One equities research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, twelve have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $28.18.

Pfizer Trading Down 1.6%

Shares of PFE stock opened at $24.45 on Friday. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.85 and a current ratio of 1.16. The stock has a fifty day simple moving average of $24.74 and a two-hundred day simple moving average of $24.35. The firm has a market capitalization of $138.99 billion, a PE ratio of 13.00, a PEG ratio of 0.81 and a beta of 0.54. Pfizer has a 52-week low of $20.92 and a 52-week high of $27.69.

Institutional Investors Weigh In On Pfizer

Several large investors have recently added to or reduced their stakes in PFE. Norges Bank purchased a new stake in Pfizer during the 2nd quarter valued at $2,270,157,000. Pacer Advisors Inc. increased its position in Pfizer by 856.8% during the first quarter. Pacer Advisors Inc. now owns 20,053,828 shares of the biopharmaceutical company’s stock valued at $508,164,000 after acquiring an additional 17,957,928 shares during the last quarter. Amundi raised its stake in shares of Pfizer by 43.4% in the first quarter. Amundi now owns 52,090,403 shares of the biopharmaceutical company’s stock valued at $1,265,277,000 after acquiring an additional 15,758,846 shares during the period. Nuveen LLC bought a new stake in shares of Pfizer in the 1st quarter worth about $389,861,000. Finally, Vanguard Group Inc. boosted its stake in shares of Pfizer by 1.9% during the 2nd quarter. Vanguard Group Inc. now owns 533,363,457 shares of the biopharmaceutical company’s stock worth $12,928,730,000 after purchasing an additional 10,198,330 shares during the period. 68.36% of the stock is owned by institutional investors.

Pfizer Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Monday, December 1st. Investors of record on Friday, November 7th will be issued a $0.43 dividend. The ex-dividend date of this dividend is Friday, November 7th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 7.0%. Pfizer’s dividend payout ratio (DPR) is presently 91.49%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.